title: (8) Cardiovascular disease and risk management.
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications / Q000517:prevention & control* / Q000628:therapy; D003327:Coronary Disease / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D048909:Diabetes Complications / Q000150:complications / Q000628:therapy*; D003920:Diabetes Mellitus / Q000628:therapy*; D019468:Disease Management; D050171:Dyslipidemias / Q000150:complications / Q000628:therapy; D058607:Fibric Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications / Q000628:therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D009525:Niacin / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D040242:Risk Reduction Behavior
chemical_list: D000959:Antihypertensive Agents; D058607:Fibric Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors; D009525:Niacin